Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 26:39:100945.
doi: 10.1016/j.gore.2022.100945. eCollection 2022 Feb.

Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus

Ruby M van Stein  1 , Christianne A R Lok  1   2 , Arend G J Aalbers  3 , Ignace H J T de Hingh  4 , Aletta P I Houwink  5 , Herman J Stoevelaar  6 , Gabe S Sonke  7 , Willemien J van Driel  1   2 ; Dutch OVHIPEC Working Group
Affiliations

Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus

Ruby M van Stein et al. Gynecol Oncol Rep. .

Abstract

Objective: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is standard of care in the Netherlands in patients with stage III epithelial ovarian cancer following interval cytoreductive surgery (CRS). Differences in patient selection, technical aspects, and perioperative management exist between centers performing HIPEC. Standardization aims to reduce unwanted variation in clinical practice. As part of an implementation process, we aimed to standardize perioperative care for patients treated with CRS and HIPEC using a Delphi-based consensus approach.

Methods: We performed a two-phase modified Delphi method involving a multidisciplinary panel of 40 experts who completed a survey on CRS and HIPEC. During a consensus meeting, survey outcomes and available scientific evidence was discussed. Items without consensus (<75% agreement) were adjusted and evaluated in a second survey.

Results: Consensus was reached in the first round on 51% of items. After two rounds, consensus was reached on the majority of items (82%) including patient selection, preoperative workup, technical aspects of CRS and HIPEC, and postoperative care. No consensus was reached on the role of HIPEC in rare ovarian cancer types, preoperative bowel preparation, timing to create bowel anastomoses, and manipulation of the perfusate.

Conclusions: Dutch experts reached consensus on most items regarding interval CRS and HIPEC for ovarian cancer. This consensus study may help to align treatment protocols and to minimize practice variation. Topics without consensus may be put on the research agenda of HIPEC for ovarian cancer.

Keywords: CRS, Cytoreductive Surgery; Consensus; Delphi; EOC, Epithelial Ovarian Cancer; HIPEC; HIPEC, Hyperthermic Intraperitoneal Chemotherapy; NACT, Neoadjuvant Chemotherapy; Ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Overview of modified Delphi process.
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68(6):394–424. - PubMed
    1. Doubeni C.A., Doubeni A.R., Myers A.E. Diagnosis and management of ovarian cancer. Am. Fam. Physician. 2016;93(11):937–944. - PubMed
    1. du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer. 2009;115(6):1234–1244. - PubMed
    1. van Driel W.J., Koole S.N., Sikorska K., Schagen van Leeuwen J.H., Schreuder H.W.R., Hermans R.H.M., de Hingh I.H.J.T., van der Velden J., Arts H.J., Massuger L.F.A.G., Aalbers A.G.J., Verwaal V.J., Kieffer J.M., Van de Vijver K.K., van Tinteren H., Aaronson N.K., Sonke G.S. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl. J. Med. 2018;378(3):230–240. - PubMed
    1. Koole S.N., van Lieshout C., van Driel W.J., van Schagen E., Sikorska K., Kieffer J.M., Schagen van Leeuwen J.H., Schreuder H.W.R., Hermans R.H., de Hingh I.H., van der Velden J., Arts H.J., Massuger L.F.A.G., Aalbers A.G., Verwaal V.J., Van de Vijver K.K., Aaronson N.K., van Tinteren H., Sonke G.S., van Harten W.H., Retèl V.P. Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial. J. Clin. Oncol. 2019;37(23):2041–2050. - PubMed